The mechanism underlying this observation might be an upregulation of LDLR expression via inhibition of the proprotein convertase subtilisin/kexin type 9 (PCSK9) by increased angiotensin II (Ang II) levels in COVID-19 patients [39]. This evidence concerns the gene PCSK9 and COVID-19.